One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

Purpose. To evaluate the effects of photodynamic therapy (PDT) combined with intravitreal injection of ranibizumab (IVR) for exudative age-related macular degeneration (AMD). Methods. Retrospective case series. Thirty eight eyes of 38 patients with exudative AMD underwent combined therapy consistin...

Full description

Bibliographic Details
Main Authors: Nakamura, Tomoko, Miyakoshi, Akio, Fujita, Kazuya, Yunoki, Tatsuya, Mitarai, Keiichi, Yanagisawa, Shuichiro, Fuchizawa, Chiharu, Hayashi, Atsushi
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235818/
id pubmed-3235818
recordtype oai_dc
spelling pubmed-32358182011-12-15 One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration Nakamura, Tomoko Miyakoshi, Akio Fujita, Kazuya Yunoki, Tatsuya Mitarai, Keiichi Yanagisawa, Shuichiro Fuchizawa, Chiharu Hayashi, Atsushi Clinical Study Purpose. To evaluate the effects of photodynamic therapy (PDT) combined with intravitreal injection of ranibizumab (IVR) for exudative age-related macular degeneration (AMD). Methods. Retrospective case series. Thirty eight eyes of 38 patients with exudative AMD underwent combined therapy consisting first of IVR, followed by PDT within a week and the second IVR at 1 month. All patients were followed up for more than 12 months. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined. Results. The mean number of IVR and PDT sessions were 2.9 ± 1.3 and 1.1 ± 0.3, respectively. The mean BCVA and CMT were significantly improved to 0.38 logMAR units (P < 0.01) and 240 μm (P < 0.01) at 12 months, respectively. Thirty-six of 38 eyes (94.8%) improved or maintained BCVA at 12 months. Conclusion. PDT combined with IVR for exudative AMD was effective at improving visual acuity and CMT with a low recurrence rate for 12 months. Hindawi Publishing Corporation 2012 2011-12-07 /pmc/articles/PMC3235818/ /pubmed/22174997 http://dx.doi.org/10.1155/2012/154659 Text en Copyright © 2012 Tomoko Nakamura et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Nakamura, Tomoko
Miyakoshi, Akio
Fujita, Kazuya
Yunoki, Tatsuya
Mitarai, Keiichi
Yanagisawa, Shuichiro
Fuchizawa, Chiharu
Hayashi, Atsushi
spellingShingle Nakamura, Tomoko
Miyakoshi, Akio
Fujita, Kazuya
Yunoki, Tatsuya
Mitarai, Keiichi
Yanagisawa, Shuichiro
Fuchizawa, Chiharu
Hayashi, Atsushi
One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
author_facet Nakamura, Tomoko
Miyakoshi, Akio
Fujita, Kazuya
Yunoki, Tatsuya
Mitarai, Keiichi
Yanagisawa, Shuichiro
Fuchizawa, Chiharu
Hayashi, Atsushi
author_sort Nakamura, Tomoko
title One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
title_short One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
title_full One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
title_fullStr One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
title_full_unstemmed One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
title_sort one-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration
description Purpose. To evaluate the effects of photodynamic therapy (PDT) combined with intravitreal injection of ranibizumab (IVR) for exudative age-related macular degeneration (AMD). Methods. Retrospective case series. Thirty eight eyes of 38 patients with exudative AMD underwent combined therapy consisting first of IVR, followed by PDT within a week and the second IVR at 1 month. All patients were followed up for more than 12 months. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined. Results. The mean number of IVR and PDT sessions were 2.9 ± 1.3 and 1.1 ± 0.3, respectively. The mean BCVA and CMT were significantly improved to 0.38 logMAR units (P < 0.01) and 240 μm (P < 0.01) at 12 months, respectively. Thirty-six of 38 eyes (94.8%) improved or maintained BCVA at 12 months. Conclusion. PDT combined with IVR for exudative AMD was effective at improving visual acuity and CMT with a low recurrence rate for 12 months.
publisher Hindawi Publishing Corporation
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235818/
_version_ 1611493257202630656

Similar Items